Cancer: Clinical Background and Key Challenges

  • Antonio Llombart-Bosch
  • Ulrik Ringborg
  • Sergio Rutella
  • Julio E. Celis
Chapter

Abstract

This chapter is aimed at a wide audience ranging from biologists to medical students and cancer specialists. It provides a comprehensive overview of systems approaches to the pathology and treatment of cancer. In particular, it addresses diagnosis and therapy by interconnecting various aspects of cancer at both the molecular and clinical level, and contrasts the unifying features of malignancies with the daunting diversity of cancer types, stages, and evolutionary processes during treatment. The importance is emphasized of both prevention and innovative treatments in reducing the cancer burden, and of early detection as the link between these two major areas. It sets the stage for analysis of cancer by means of systems biology, bioinformatics, and systems medicine. These methods involve the processing of cytological, histological, and imaging data, combined with genetic and expression profiling. The application of systems approaches to cancer-related clinical practice and research is discussed. The necessity is demonstrated for signalling pathways analysis to be fully integrated into grading and clinical staging of cancers, as well as into the process of discovering novel targets and biomarkers for diagnosis and prognosis. Key challenges and limitations are outlined for systems approaches to cancer, and areas are indicated where research needs to be focused in the future. Finally, pointers are provided to the paths that must be followed in order to move from a carefully controlled biological investigation, to approaches and technologies that will eventually accelerate the translation of new discoveries into prevention and clinical applications.

Keywords

Epidermal Growth Factor Receptor Acute Promyelocytic Leukaemia Tumour Node Metastasis Small Round Cell Tumour Cellular Blue Nevus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

We are indebted to Laila Fischer for expert secretarial assistance. This work was supported by the IVO Cancer Institute and the EuroBoNeT consortium, a network of excellence granted by the European Commission for studying the pathology and genetics of bone tumours (to ALLB), the Stockholm Cancer Society (to UR), and the Danish Cancer Society, the Danish Medical Research Council, and the John and Birthe Meyer Foundation (to JEC).

References

  1. Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, Gillies McKenna W (2008) Abeloff’s clinical oncology, 4th edn. Churchill Livingstone, UKGoogle Scholar
  2. Aebersold R, Auffray C, Baney E, Barillot E, Brazma A, Brett C, Brunak S, Butte A, Califano A, Celis J, Cufer T, Ferrell J, Galas D, Gallahan D, Gatenby R, Goldbeter A, Hace N, Henney A, Hood L, Iyengar R, Jackson V, Kallioniemi O, Klingmuller U, Kolar P, Kolch W, Kyriakopoulou C, Laplace F, Lehrach H, Marcus F, Matrisian L, Nolan G, Pelkmans L, Potti A, Sander C, Seljak M, Singer D, Sorger P, Stunnenberg H, Superti-Furga G, Uhlen M, Vidal M, Weinstein J, Wigle D, Williams M, Wolkenhauer O, Zhivotovsky B, Zinovyev A, Zupan B (2009) Report on EU-USA workshop: how systems biology can advance cancer research (27 October 2008). Mol Oncol 3(1):9–17PubMedCrossRefGoogle Scholar
  3. Aitken JF, Elwood M, Baade PD, Youl P, English D (2010) Clinical whole-body skin examination reduces the incidence of thick melanomas. Int J Cancer 126(2):450–458PubMedCrossRefGoogle Scholar
  4. Albertsen P (2009) Androgen deprivation in prostate cancer—step by step. N Engl J Med 360(24):2572–2574PubMedCrossRefGoogle Scholar
  5. Alymani NA, Smith MD, Williams DJ, Petty RD (2010) Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation. Eur J Cancer 46(5):869–879PubMedCrossRefGoogle Scholar
  6. Aparicio SA, Huntsman DG (2010) Does massively parallel DNA resequencing signify the end of histopathology as we know it? J Pathol 220(2):307–315PubMedGoogle Scholar
  7. Arisio R, Cuccorese C, Accinelli G, Mano MP, Bordon R, Fessia L (1998) Role of fine-needle aspiration biopsy in breast lesions: analysis of a series of 4110 cases. Diagn Cytopathol 18(6):462–467PubMedCrossRefGoogle Scholar
  8. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27(35):6041–6051PubMedCrossRefGoogle Scholar
  9. Badve S, Nakshatri H (2009) Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J Clin Pathol 62(1):6–12PubMedCrossRefGoogle Scholar
  10. Balch C, Houghton A, Sober A, Soong S (2003) Cutaneous melanoma, 4th edn. Quality Medical, St LouisGoogle Scholar
  11. Baselga J (2006) Targeting tyrosine kinases in cancer: the second wave. Science 312(5777):1175–1178PubMedCrossRefGoogle Scholar
  12. Baselga J, Arribas J (2004) Treating cancer’s kinase ‘addiction’. Nat Med 10(8):786–787PubMedCrossRefGoogle Scholar
  13. Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9(7):463–475PubMedCrossRefGoogle Scholar
  14. Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, Drugge N, Ekberg L, Friesland S, Johansson KA, Lund JA, Morhed E, Nilsson K, Levin N, Paludan M, Sederholm C, Traberg A, Wittgren L, Lewensohn R (2009) Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 27(20):3290–3296PubMedCrossRefGoogle Scholar
  15. Beckman M (2006) Tumor complexity prompts caution about sequencing. J Natl Cancer Inst 98(24):1758–1759PubMedCrossRefGoogle Scholar
  16. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3(6):401–410PubMedCrossRefGoogle Scholar
  17. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353(17):1784–1792PubMedCrossRefGoogle Scholar
  18. Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11(3):359–377PubMedCrossRefGoogle Scholar
  19. Bobola MS, Silber JR, Ellenbogen RG, Geyer JR, Blank A, Goff RD (2005) O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines. Clin Cancer Res 11(7):2747–2755PubMedCrossRefGoogle Scholar
  20. Boffetta P, Hashibe M (2006) Alcohol and cancer. Lancet Oncol 7(2):149–156PubMedCrossRefGoogle Scholar
  21. Bosman FT (1995) Prognostic value of pathological characteristics of colorectal cancer. Eur J Cancer 31A(7–8):1216–1221PubMedCrossRefGoogle Scholar
  22. Boyle P, Autier P, Bartelink H, Baselga J, Boffetta P, Burn J, Burns HJ, Christensen L, Denis L, Dicato M, Diehl V, Doll R, Franceschi S, Gillis CR, Gray N, Griciute L, Hackshaw A, Kasler M, Kogevinas M, Kvinnsland S, La VC, Levi F, McVie JG, Maisonneuve P, Martin-Moreno JM, Bishop JN, Oleari F, Perrin P, Quinn M, Richards M, Ringborg U, Scully C, Siracka E, Storm H, Tubiana M, Tursz T, Veronesi U, Wald N, Weber W, Zaridze DG, Zatonski W, Zur HH (2003a) European code against cancer and scientific justification: third version. Ann Oncol 14(7):973–1005CrossRefGoogle Scholar
  23. Boyle P, d’Onofrio A, Maisonneuve P, Severi G, Robertson C, Tubiana M, Veronesi U (2003b) Measuring progress against cancer in Europe: has the 15% decline targeted for 2000 come about? Ann Oncol 14(8):1312–1325CrossRefGoogle Scholar
  24. Boyle P, Levin B (2008) World cancer report. http://www.iarc.fr/en/publications/pdfs-online/wcr/2008/index.php
  25. Brenton JD, Carey LA, Ahmed AA, Caldas C (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23(29):7350–7360PubMedCrossRefGoogle Scholar
  26. Bridge RS, Rajaram V, Dehner LP, Pfeifer JD, Perry A (2006) Molecular diagnosis of Ewing sarcoma/primitive neuroectodermal tumor in routinely processed tissue: a comparison of two FISH strategies and RT-PCR in malignant round cell tumors. Mod Pathol 19(1):1–8PubMedCrossRefGoogle Scholar
  27. Celis JE (2008) Editorial. Mol Oncol 2(1):1–1CrossRefGoogle Scholar
  28. Celis JE, Gromov P (2003) Proteomics in translational cancer research: toward an integrated approach. Cancer Cell 3(1):9–15PubMedCrossRefGoogle Scholar
  29. Celis JE, Gromov P, Cabezon T, Moreira JM, Ambartsumian N, Sandelin K, Rank F, Gromova I (2004) Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics 3(4):327–344PubMedCrossRefGoogle Scholar
  30. Celis JE, Gromov P, Cabezon T, Moreira JM, Friis E, Jirstrom K, Llombart-Bosch A, Timmermans-Wielenga V, Rank F, Gromova I (2008) 15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma. Mol Cell Proteomics 7(10):1795–1809PubMedCrossRefGoogle Scholar
  31. Celis JE, Gromov P, Gromova I, Moreira JM, Cabezon T, Ambartsumian N, Grigorian M, Lukanidin E, thor Straten P, Guldberg P, Bartkova J, Bartek J, Lukas J, Lukas C, Lykkesfeldt A, Jaattela M, Roepstorff P, Bolund L, Orntoft T, Brunner N, Overgaard J, Sandelin K, Blichert-Toft M, Mouridsen H, Rank FE (2003) Integrating proteomic and functional genomic technologies in discovery-driven translational breast cancer research. Mol Cell Proteomics 2(6):369–377PubMedGoogle Scholar
  32. Celis JE, Gromova I, Cabezon T, Gromov P, Shen T, Timmermans-Wielenga V, Rank F, Moreira JM (2007) Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease. Mol Oncol 1(3):321–349PubMedCrossRefGoogle Scholar
  33. Celis JE, Moreira JM, Gromova I, Cabezon T, Ralfkiaer U, Guldberg P, Straten PT, Mouridsen H, Friis E, Holm D, Rank F, Gromov P (2005) Towards discovery-driven translational research in breast cancer. FEBS J 272(1):2–15PubMedCrossRefGoogle Scholar
  34. Chabner BA, Longo DL (2006) Cancer chemotherapy and biotherapy. Principles and practice, 4th edn. Lippincott Williams & Wilkins, BaltimoreGoogle Scholar
  35. Chan JK (2001) The new world health organization classification of lymphomas: the past, the present and the future. Hematol Oncol 19(4):129–150PubMedCrossRefGoogle Scholar
  36. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14(5):1368–1376PubMedCrossRefGoogle Scholar
  37. Chiang AC, Massague J (2008) Molecular basis of metastasis. N Engl J Med 359(26):2814–2823PubMedCrossRefGoogle Scholar
  38. Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, Godwin J, Goldhirsch A, Gray R, Peto R, Pritchard KI, Wood WC (2008) Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 371(9606):29–40PubMedCrossRefGoogle Scholar
  39. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106PubMedGoogle Scholar
  40. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F (2005) Carcinogenicity of human papillomaviruses. Lancet Oncol 6(4):204PubMedCrossRefGoogle Scholar
  41. Cohn-Cedermark G, Rutqvist LE, Andersson R, Breivald M, Ingvar C, Johansson H, Jonsson PE, Krysander L, Lindholm C, Ringborg U (2000) Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8–2.0 mm. Cancer 89(7):1495–1501PubMedCrossRefGoogle Scholar
  42. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, Barow M, Mountford JC, Holyoake TL (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107(11):4532–4539PubMedCrossRefGoogle Scholar
  43. Correa Geyer F, Reis-Filho JS (2009) Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet? Int J Surg Pathol 17(4):285–302PubMedCrossRefGoogle Scholar
  44. Costa J (2009) Systems approach to the practice of pathology: a new role for the pathologist. Arch Pathol Lab Med 133(4):524–526PubMedGoogle Scholar
  45. Cotterill SJ, Ahrens S, Paulussen M, Jurgens HF, Voute PA, Gadner H, Craft AW (2000) Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol 18(17):3108–3114PubMedGoogle Scholar
  46. Cuppone F, Bria E, Carlini P, Milella M, Felici A, Sperduti I, Nistico C, Terzoli E, Cognetti F, Giannarelli D (2008) Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. Cancer 113(2):238–246PubMedCrossRefGoogle Scholar
  47. Dardick I, Herrera GA (1998) Diagnostic electron microscopy of neoplasms. Hum Pathol 29(12):1335–1338PubMedCrossRefGoogle Scholar
  48. Alava E de, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG, Gerald WL, Jhanwar SC, Argani P, Antonescu CR, Pardo-Mindan FJ, Ginsberg J, Womer R, Lawlor ER, Wunder J, Andrulis I, Sorensen PH, Barr FG, Ladanyi M (1998) EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing’s sarcoma. J Clin Oncol 16(4):1248–1255PubMedGoogle Scholar
  49. Delattre O (2008) Ewing’s tumours, genetic and cellular aspects. Pathol Biol (Paris) 56(5):257–259PubMedCrossRefGoogle Scholar
  50. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15):4429–4434PubMedCrossRefGoogle Scholar
  51. Desmedt C, Ruiz-Garcia E, Andre F (2008) Gene expression predictors in breast cancer: current status, limitations and perspectives. Eur J Cancer 44(18):2714–2720PubMedCrossRefGoogle Scholar
  52. DeVita VT Jr, Hellman S, Rosenberg SA (2008) Cancer: principles and practice of oncology. Lippincott Williams and Wilkins, BaltimoreGoogle Scholar
  53. Doll R, Peto R, Boreham J, Sutherland I (2004) Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ 328(7455):1519PubMedCrossRefGoogle Scholar
  54. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28(3):509–518PubMedCrossRefGoogle Scholar
  55. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031–1037PubMedCrossRefGoogle Scholar
  56. Duff SE, Jeziorska M, Rosa DD, Kumar S, Haboubi N, Sherlock D, O’Dwyer ST, Jayson GC (2006) Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy. Eur J Cancer 42(1):112–117PubMedCrossRefGoogle Scholar
  57. Dworak O, Keilholz L, Hoffmann A (1997) Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12(1):19–23PubMedCrossRefGoogle Scholar
  58. Eden P, Ritz C, Rose C, Ferno M, Peterson C (2004) “Good Old” clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 40(12):1837–1841PubMedCrossRefGoogle Scholar
  59. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging manual, 7th edn. Springer, BerlinGoogle Scholar
  60. Ehrlich Y, Brames MJ, Beck SD, Foster RS, Einhorn LH (2010) Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol 28(4):531–536PubMedCrossRefGoogle Scholar
  61. Elston C, Ellis I (1998) Systemic pathology: the breast. Elsevier, Churchill Livingstone, LondonGoogle Scholar
  62. Espina V, Heiby M, Pierobon M, Liotta LA (2007) Laser capture microdissection technology. Expert Rev Mol Diagn 7(5):647–657PubMedCrossRefGoogle Scholar
  63. Esteller M (2008) Epigenetics in cancer. N Engl J Med 358(11):1148–1159PubMedCrossRefGoogle Scholar
  64. Faratian D, Bartlett J (2008) Predictive markers in breast cancer—the future. Histopathology 52(1):91–98PubMedCrossRefGoogle Scholar
  65. Fass L (2008) Imaging and cancer: a review. Mol Oncol 2(2):115–152PubMedCrossRefGoogle Scholar
  66. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61(5):759–767PubMedCrossRefGoogle Scholar
  67. Fellinger EJ, Garin-Chesa P, Su SL, DeAngelis P, Lane JM, Rettig WJ (1991) Biochemical and genetic characterization of the HBA71 Ewing’s sarcoma cell surface antigen. Cancer Res 51(1):336–340PubMedGoogle Scholar
  68. Fenoglio-Preiser CM, Noffsinger AE, Stemmermann GN (1999) Gastrointestinal pathology: an atlas and text. Lippincott Williams & Wilkins, BaltimoreGoogle Scholar
  69. Ferlay J, Parkin DM, Steliarova-Foucher E (2010a) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46(4):765–781CrossRefGoogle Scholar
  70. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010b) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917Google Scholar
  71. Fletcher SW, Elmore JG (2003) Clinical practice. Mammographic screening for breast cancer. N Engl J Med 348(17):1672–1680Google Scholar
  72. Folpe AL, Goldblum JR, Rubin BP, Shehata BM, Liu W, Dei Tos AP, Weiss SW (2005) Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol 29(8):1025–1033PubMedGoogle Scholar
  73. Francisci S, Capocaccia R, Grande E, Santaquilani M, Simonetti A, Allemani C, Gatta G, Sant M, Zigon G, Bray F, Janssen-Heijnen M (2009) The cure of cancer: a European perspective. Eur J Cancer 45(6):1067–1079PubMedCrossRefGoogle Scholar
  74. Franklin W, Muller KM, Wistuba II, Sozzi G, Geisinger K, Brambilla E, Lam S, Gazdar A, Hirsch FR (2004) Squamous dysplasia and carcinoma in situ. Pathology and genetics of tumours of the lung, pleura, thymus and heart. WHO—IARC press, LyonGoogle Scholar
  75. Gravendeel LA, Kouwenhoven MC, Gevaert O, Rooi JJ de, Stubbs AP, Duijm JE, Daemen A, Bleeker FE, Bralten LB, Kloosterhof NK, De MB, Eilers PH, Spek PJ van der, Kros JM, Sillevis Smitt PA, Bent MJ van den, French PJ (2009) Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 69(23):9065–9072PubMedCrossRefGoogle Scholar
  76. Hahn WC, Weinberg RA (2002) Modelling the molecular circuitry of cancer. Nat Rev Cancer 2(5):331–341PubMedCrossRefGoogle Scholar
  77. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, Gaulard P, Garderet L, Lepage E, Reyes F, Meignan M (2005) [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106(4):1376–1381PubMedCrossRefGoogle Scholar
  78. Hamilton SR, Aaltonen LA (2000) Pathology & genetics of tumours of the digestive system. WHO—IARCPress, LyonGoogle Scholar
  79. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70PubMedCrossRefGoogle Scholar
  80. Hansen RJ, Nagasubramanian R, Delaney SM, Samson LD, Dolan ME (2007) Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice. Carcinogenesis 28(5):1111–1116PubMedCrossRefGoogle Scholar
  81. Hasegawa T, Hirose T, Ayala AG, Ito S, Tomaru U, Matsuno Y, Shimoda T, Hirohashi S (2001) Adult neuroblastoma of the retroperitoneum and abdomen: clinicopathologic distinction from primitive neuroectodermal tumor. Am J Surg Pathol 25(7):918–924PubMedCrossRefGoogle Scholar
  82. Hayes BD, Quinn CM (2009) Pathology of B3 lesions of the breast. Diagnostic Histopathol 15(10):459–469CrossRefGoogle Scholar
  83. Heinrich MC, Corless CL (2004) Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomas. Cancer Treat Res 120:129–150PubMedCrossRefGoogle Scholar
  84. Heinrich MC, Corless CL, Demetri GD, Blanke CD, Mehren von M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21(23):4342–4349PubMedCrossRefGoogle Scholar
  85. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359(13):1367–1380PubMedCrossRefGoogle Scholar
  86. Hoos A, Stojadinovic A, Mastorides S, Urist MJ, Polsky D, Di Como CJ, Brennan MF, Cordon-Cardo C (2001) High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. Cancer 92(4):869–874PubMedCrossRefGoogle Scholar
  87. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72(2):567–572PubMedGoogle Scholar
  88. Hutter RV, Sobin LH (1986) A universal staging system for cancer of the colon and rectum. Let there be light. Arch Pathol Lab Med 110(5):367–368PubMedGoogle Scholar
  89. Ingoldsby H, Callagy G (2009) Pathology of minimal metastatic disease in sentinel lymph nodes in breast cancer. Diagn Histopathol 15(10):470–477CrossRefGoogle Scholar
  90. Jakel O, Karger CP, Debus J (2008) The future of heavy ion radiotherapy. Med Phys 35(12):5653–5663PubMedCrossRefGoogle Scholar
  91. Jass JR (2007) Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50(1):113–130PubMedCrossRefGoogle Scholar
  92. Jin L, Lloyd RV (1997) In situ hybridization: methods and applications. J Clin Lab Anal 11(1):2–9PubMedCrossRefGoogle Scholar
  93. Kallioniemi OP, Wagner U, Kononen J, Sauter G (2001) Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 10(7):657–662PubMedCrossRefGoogle Scholar
  94. Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6(5):392–401PubMedCrossRefGoogle Scholar
  95. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14):2137–2150PubMedCrossRefGoogle Scholar
  96. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O’Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346(9):645–652PubMedCrossRefGoogle Scholar
  97. Kauer M, Ban J, Kofler R, Walker B, Davis S, Meltzer P, Kovar H (2009) A molecular function map of Ewing’s sarcoma. PLoS One 4(4):e5415PubMedCrossRefGoogle Scholar
  98. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19):2039–2049PubMedCrossRefGoogle Scholar
  99. Khan J, Wei JS, Ringner M, Saal LH, Ladanyi M, Westermann F, Berthold F, Schwab M, Antonescu CR, Peterson C, Meltzer PS (2001) Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 7(6):673–679PubMedCrossRefGoogle Scholar
  100. Kovar H, Jug G, Aryee DN, Zoubek A, Ambros P, Gruber B, Windhager R, Gadner H (1997) Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 15(18):2225–2232PubMedCrossRefGoogle Scholar
  101. Kreeger PK, Lauffenburger DA (2010) Cancer systems biology: a network modeling perspective. Carcinogenesis 31(1):2–8PubMedCrossRefGoogle Scholar
  102. Ladanyi M (1995) The emerging molecular genetics of sarcoma translocations. Diagn Mol Pathol 4(3):162–173PubMedCrossRefGoogle Scholar
  103. Lango MN (2009) Multimodal treatment for head and neck cancer. Surg Clin North Am 89(1):43–52PubMedCrossRefGoogle Scholar
  104. Laubenbacher R, Hower V, Jarrah A, Torti SV, Shulaev V, Mendes P, Torti FM, Akman S (2009) A systems biology view of cancer. Biochim Biophys Acta 1796(2):129–139PubMedGoogle Scholar
  105. Levitt SH, Perez CA, Hui S, Purdy JA (2008) Evolution of computerized radiotherapy in radiation oncology: potential problems and solutions. Int J Radiat Oncol Biol Phys 70(4):978–986CrossRefGoogle Scholar
  106. Levitt SH, Purdy JA, Perez CA, Vijayakumar S (2006) Technical basis of radiation therapy. Practical clinical applications, 4th edn. Lippincott Williams & Wilkins, BaltimoreCrossRefGoogle Scholar
  107. Liu CL, Prapong W, Natkunam Y, Alizadeh A, Montgomery K, Gilks CB, Rijn M van de (2002) Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol 161(5):1557–1565PubMedCrossRefGoogle Scholar
  108. Llombart-Bosch A (2001) De la anatomia patologica estructural a la patologia molecular. Discurso de Recepcion. Real Academia de Medicina de la Comunidad Valenciana. RAMCV Press, Valencia, SpainGoogle Scholar
  109. Llombart-Bosch A, Contesso G, Peydro-Olaya A (1996) Histology, immunohistochemistry, and electron microscopy of small round cell tumors of bone. Semin Diagn Pathol 13(3):153–170PubMedGoogle Scholar
  110. Llombart-Bosch A, Machado I, Navarro S, Bertoni F, Bacchini P, Alberghini M, Karzeladze A, Savelov N, Petrov S, varado-Cabrero I, Mihaila D, Terrier P, Lopez-Guerrero JA, Picci P (2009) Histological heterogeneity of Ewing’s sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support. Virchows Arch 455(5):397–411PubMedCrossRefGoogle Scholar
  111. Llombart-Bosch A, Navarro S (2001) Immunohistochemical detection of EWS and FLI-1 proteinss in Ewing sarcoma and primitive neuroectodermal tumors: comparative analysis with CD99 (MIC-2) expression. Appl Immunohistochem Mol Morphol 9(3):255–260PubMedCrossRefGoogle Scholar
  112. Lopez-Guerrero JA, Machado I, Scotlandi K, Noguera R, Pellin A, Navarro S, Serra M, Calabuig-Farinas S, Picci P, Llombart-Bosch A (2011) Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing’s sarcoma family of tumors. Int J Cancer 128(5):1139–1150Google Scholar
  113. Lopez-Guerrero JA, Llombart-Cussac A, Noguera R, Navarro S, Pellin A, Almenar S, Vazquez-Alvadalejo C, Llombart-Bosch A (2006) HER2 amplification in recurrent breast cancer following breast-conserving therapy correlates with distant metastasis and poor survival. Int J Cancer 118(7):1743–1749PubMedCrossRefGoogle Scholar
  114. Lopez-Guerrero JA, Pellin A, Noguera R, Carda C, Llombart-Bosch A (2001) Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors. Lab Invest 81(6):803–814PubMedCrossRefGoogle Scholar
  115. Lynch HT, la Chapelle A de (2003) Hereditary colorectal cancer. N Engl J Med 348(10):919–932PubMedCrossRefGoogle Scholar
  116. Machado I, Noguera R, Pellin A, Lopez-Guerrero JA, Piqueras M, Navarro S, Llombart-Bosch A (2009) Molecular diagnosis of Ewing sarcoma family of tumors: a comparative analysis of 560 cases with FISH and RT-PCR. Diagn Mol Pathol 18(4):189–199PubMedCrossRefGoogle Scholar
  117. Madarnas Y, Trudeau M, Franek JA, McCready D, Pritchard KI, Messersmith H (2008) Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review. Cancer Treat Rev 34(6):539–557CrossRefGoogle Scholar
  118. Marie JP, Zittoun R, Sikic BI (1991) Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78(3):586–592PubMedGoogle Scholar
  119. Markowitz SD, Bertagnolli MM (2009) Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 361(25):2449–2460PubMedCrossRefGoogle Scholar
  120. McCafferty MPJ, Healy NA, Kerin MJ (2009) Breast cancer subtypes and molecular biomarkers. Diagn Histopathol 15(10):485–489CrossRefGoogle Scholar
  121. Meara RS, Cangiarella J, Simsir A, Horton D, Eltoum I, Chhieng DC (2007) Prediction of aggressiveness of gastrointestinal stromal tumours based on immunostaining with bcl-2, Ki-67 and p53. Cytopathology 18(5):283–289PubMedCrossRefGoogle Scholar
  122. Mehlen P, Puisieux A (2006) Metastasis: a question of life or death. Nat Rev Cancer 6(6):449–458PubMedCrossRefGoogle Scholar
  123. Meyer T, Hart IR (1998) Mechanisms of tumour metastasis. Eur J Cancer 34(2):214–221PubMedCrossRefGoogle Scholar
  124. Nagtegaal ID, Krieken JH van (2002) The role of pathologists in the quality control of diagnosis and treatment of rectal cancer-an overview. Eur J Cancer 38(7):964–972PubMedCrossRefGoogle Scholar
  125. Naora H, Montell DJ (2005) Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 5(5):355–366CrossRefGoogle Scholar
  126. Natkunam Y, Mason DY (2006) Prognostic immunohistologic markers in human tumors: why are so few used in clinical practice? Lab Invest 86(8):742–747PubMedCrossRefGoogle Scholar
  127. Navarro S, Giraudo P, Karseladze AI, Smirnov A, Petrovichev N, Savelov N, Varado-Cabrero I, Llombart-Bosch A (2007) Immunophenotypic profile of biomarkers related to anti-apoptotic and neural development pathways in the Ewing’s family of tumors (EFT) and their therapeutic implications. Anticancer Res 27(4B):2457–2463PubMedGoogle Scholar
  128. Nguyen DX, Bos PD, Massague J (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9(4):274–284PubMedCrossRefGoogle Scholar
  129. Nilsson G, Wang M, Wejde J, Kreicbergs A, Larsson O (1999) Detection of EWS/FLI-1 by immunostaining. An adjunctive tool in diagnosis of Ewing’s sarcoma and primitive neuroectodermal tumour on cytological samples and paraffin-embedded archival material. Sarcoma 3(1):25–32PubMedCrossRefGoogle Scholar
  130. Nirmalanandhan VS, Sittampalam GS (2009) Stem cells in drug discovery, tissue engineering, and regenerative medicine: emerging opportunities and challenges. J Biomol Screen 14(7):755–768PubMedCrossRefGoogle Scholar
  131. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11):994–1004PubMedCrossRefGoogle Scholar
  132. O’Shaughnessy JA (2006) Molecular signatures predict outcomes of breast cancer. N Engl J Med 355(6):615–617PubMedCrossRefGoogle Scholar
  133. Ordonez NG, Mackay B (1998) Electron microscopy in tumor diagnosis: indications for its use in the immunohistochemical era. Hum Pathol 29(12):1403–1411CrossRefGoogle Scholar
  134. Parham DM, Hijazi Y, Steinberg SM, Meyer WH, Horowitz M, Tzen CY, Wexler LH, Tsokos M (1999) Neuroectodermal differentiation in Ewing’s sarcoma family of tumors does not predict tumor behavior. Hum Pathol 30(8):911–918PubMedCrossRefGoogle Scholar
  135. Parkin DM (2004) International variation. Oncogene 23(38):6329–6340PubMedCrossRefGoogle Scholar
  136. Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Minna JD (2000) Lung cancer: principles and practice, 2nd edn. Lippincott Williams & Wilkins, BaltimoreGoogle Scholar
  137. Patz EF Jr, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE (2007) Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 25(35):5578–5583PubMedCrossRefGoogle Scholar
  138. Payne SJ, Bowen RL, Jones JL, Wells CA (2008) Predictive markers in breast cancer—the present. Histopathology 52(1):82–90PubMedCrossRefGoogle Scholar
  139. Perou CM, Sorlie T, Eisen MB, Rijn M van de, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752PubMedCrossRefGoogle Scholar
  140. Pinero-Madrona A, Polo-Garcia L, Onso-Romero JL, Salinas-Ramos J, Canteras-Jordana M, Sola-Perez J, Galindo-Fernandez PJ, Illana-Moreno J, Bermejo-Lopez J, Navarrete-Montoya A, Parrilla-Paricio P (2008) Immunohistochemical characterisation of breast cancer: towards a new clasification? Cir Esp 84(3):138–145PubMedCrossRefGoogle Scholar
  141. Pinkerton R, Matthay K, Shankar AG (2007) Evidence-based pediatric oncology, 2nd edn. Blackwell, OxfordCrossRefGoogle Scholar
  142. Pleasance ED, Stephens PJ, O’Meara S, McBride DJ, Meynert A, Jones D, Lin ML, Beare D, Lau KW, Greenman C, Varela I, Nik-Zainal S, Davies HR, Ordonez GR, Mudie LJ, Latimer C, Edkins S, Stebbings L, Chen L, Jia M, Leroy C, Marshall J, Menzies A, Butler A, Teague JW, Mangion J, Sun YA, McLaughlin SF, Peckham HE, Tsung EF, Costa GL, Lee CC, Minna JD, Gazdar A, Birney E, Rhodes MD, McKernan KJ, Stratton MR, Futreal PA, Campbell PJ (2010) A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463(7278):184–190PubMedCrossRefGoogle Scholar
  143. Ponten J (2001) Cell biology of precancer. Eur J Cancer 37(Suppl 8):97–113CrossRefGoogle Scholar
  144. Rakha EA, Putti TC, bd El-Rehim DM, Paish C, Green AR, Powe DG, Lee AH, Robertson JF, Ellis IO (2006) Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 208(4):495–506CrossRefGoogle Scholar
  145. Ransohoff DF (2009) Promises and limitations of biomarkers. Recent Results Cancer Res 181:55–59PubMedCrossRefGoogle Scholar
  146. Reis-Filho JS, Westbury C, Pierga JY (2006) The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol 59(3):225–231PubMedCrossRefGoogle Scholar
  147. Richards MA (2009) The size of the prize for earlier diagnosis of cancer in England. Br J Cancer 101(Suppl 2):S125–S129PubMedCrossRefGoogle Scholar
  148. Ringborg U, Bergqvist D, Brorsson B, Cavallin-Stahl E, Ceberg J, Einhorn N, Frodin JE, Jarhult J, Lamnevik G, Lindholm C, Littbrand B, Norlund A, Nylen U, Rosen M, Svensson H, Moller TR (2003) The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001—summary and conclusions. Acta Oncol 42(5–6):357–365PubMedCrossRefGoogle Scholar
  149. Rosai J (2001) The continuing role of morphology in the molecular age. Mod Pathol 14(3):258–260PubMedCrossRefGoogle Scholar
  150. Rosai J (2007) Why microscopy will remain a cornerstone of surgical pathology. Lab Invest 87(5):403–408PubMedCrossRefGoogle Scholar
  151. Rosai J, Ackerman LV (1996) Ackerman’s surgical pathology. CRC Press, Boca RatonGoogle Scholar
  152. Saad RS, Kordunsky L, Liu YL, Denning KL, Kandil HA, Silverman JF (2006) Lymphatic microvessel density as prognostic marker in colorectal cancer. Mod Pathol 19(10):1317–1323PubMedCrossRefGoogle Scholar
  153. Sanchez-Garcia I (2009) The crossroads of oncogenesis and metastasis. N Engl J Med 360(3):297–299PubMedCrossRefGoogle Scholar
  154. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550PubMedCrossRefGoogle Scholar
  155. Sara H, Kallioniemi O, Nees M (2010) A decade of cancer gene profiling: from molecular portraits to molecular function. Methods Mol Biol 576:61–87PubMedCrossRefGoogle Scholar
  156. Sarkaria JN, Bristow RG (2008) Overview of cancer molecular radiobiology. Cancer Treat Res 139:117–133PubMedGoogle Scholar
  157. Schoenberg Fejzo M, Slamon DJ (2001) Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. Am J Pathol 159(5):1645–1650PubMedCrossRefGoogle Scholar
  158. Sharma R, Hamilton A, Beith J (2008) LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev (4):CD004562Google Scholar
  159. Shepherd FA, Rodrigues PJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, Kooten M van, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123–132PubMedCrossRefGoogle Scholar
  160. Shergill IS, Shergill NK, Arya M, Patel HR (2004) Tissue microarrays: a current medical research tool. Curr Med Res Opin 20(5):707–712PubMedCrossRefGoogle Scholar
  161. Shia J, Ellis NA, Paty PB, Nash GM, Qin J, Offit K, Zhang XM, Markowitz AJ, Nafa K, Guillem JG, Wong WD, Gerald WL, Klimstra DS (2003) Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol 27(11):1407–1417PubMedCrossRefGoogle Scholar
  162. Simunovic M, Smith AJ, Heald RJ (2009) Rectal cancer surgery and regional lymph nodes. J Surg Oncol 99(4):256–259CrossRefGoogle Scholar
  163. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182PubMedCrossRefGoogle Scholar
  164. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez RP, Piccart-Gebhart MJ (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369(9555):29–36PubMedCrossRefGoogle Scholar
  165. Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant tumours, 7th edn. Wiley-Blackwell, OxfordGoogle Scholar
  166. Sorlie T, Perou CM, Fan C, Geisler S, Aas T, Nobel A, Anker G, Akslen LA, Botstein D, Borresen-Dale AL, Lonning PE (2006) Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther 5(11):2914–2918PubMedCrossRefGoogle Scholar
  167. Spira A, Ettinger DS (2004) Multidisciplinary management of lung cancer. N Engl J Med 350(4):379–392PubMedCrossRefGoogle Scholar
  168. Tang P, Skinner KA, Hicks DG (2009) Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready? Diagn Mol Pathol 18(3):125–132PubMedCrossRefGoogle Scholar
  169. Tavassoli FA, Devilee P (2003) Pathology & genetics: tumours of the breast and female genital organs. IARC press—WHO, LyonGoogle Scholar
  170. Taylor CR, Cote RJ (1997) Immunohistochemical markers of prognostic value in surgical pathology. Histol Histopathol 12(4):1039–1055PubMedGoogle Scholar
  171. Terrier P, Henry-Amar M, Triche TJ, Horowitz ME, Terrier-Lacombe MJ, Miser JS, Kinsella TJ, Contesso G, Llombart-Bosch A (1995) Is neuro-ectodermal differentiation of Ewing’s sarcoma of bone associated with an unfavourable prognosis? Eur J Cancer 31A(3):307–314PubMedCrossRefGoogle Scholar
  172. Thun MJ, Henley SJ, Burns D, Jemal A, Shanks TG, Calle EE (2006) Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst 98(10):691–699PubMedCrossRefGoogle Scholar
  173. Tlsty TD, Coussens LM (2006) Tumor stroma and regulation of cancer development. Annu Rev Pathol 1:119–150PubMedCrossRefGoogle Scholar
  174. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (2004) Pathology & genetics of tumours of the lung, pleura, thymus and heart. IARC press—WHO, LyonGoogle Scholar
  175. Trigg ME, Sather HN, Reaman GH, Tubergen DG, Steinherz PG, Gaynon PS, Uckun FM, Hammond GD (2008) Ten-year survival of children with acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Leuk Lymphoma 49(6):1142–1154PubMedCrossRefGoogle Scholar
  176. Ueda T, Aozasa K, Tsujimoto M, Ohsawa M, Uchida A, Aoki Y, Ono K, Matsumoto K (1989) Prognostic significance of Ki-67 reactivity in soft tissue sarcomas. Cancer 63(8):1607–1611PubMedCrossRefGoogle Scholar
  177. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani, Boer JM, Beverloo HB, Moorhouse MJ, Spek PJ van der, Lowenberg B, Delwel R (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350(16):1617–1628PubMedCrossRefGoogle Scholar
  178. Oosterom AT van, Judson I, Verweij J, Stroobants S, di Donato PE, Dimitrijevic S, Martens M, Webb A, Sciot R, Van GM, Silberman S, Nielsen OS (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358(9291):1421–1423PubMedCrossRefGoogle Scholar
  179. Verellen D, Ridder MD, Linthout N, Tournel K, Soete G, Storme G (2007) Innovations in image-guided radiotherapy. Nat Rev Cancer 7(12):949–960PubMedCrossRefGoogle Scholar
  180. Watt FM, Driskell RR (2010) The therapeutic potential of stem cells. Philos Trans R Soc Lond B Biol Sci 365(1537):155–163PubMedCrossRefGoogle Scholar
  181. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21(1):16–19PubMedCrossRefGoogle Scholar
  182. Weidner N, Tjoe J (1994) Immunohistochemical profile of monoclonal antibody O13: antibody that recognizes glycoprotein p30/32MIC2 and is useful in diagnosing Ewing’s sarcoma and peripheral neuroepithelioma. Am J Surg Pathol 18(5):486–494PubMedCrossRefGoogle Scholar
  183. Weigelt B, Peterse JL, van’t Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5(8):591–602PubMedCrossRefGoogle Scholar
  184. Weinberg RA (2007) Biology of cancer. Garland Science, LondonGoogle Scholar
  185. Whitehead R (1994) Gastrointestinal and oesohageal pathology. Churchill Livingstone, LondonGoogle Scholar
  186. Witz IP (2009) The tumor microenvironment: the making of a paradigm. Cancer Microenviron 2(Suppl 1):9–17PubMedCrossRefGoogle Scholar
  187. Yamanaka R, Saya H (2009) Molecularly targeted therapies for glioma. Ann Neurol 66(6):717–729PubMedCrossRefGoogle Scholar
  188. Zambelli D, Zuntini M, Nardi F, Manara MC, Serra M, Landuzzi L, Lollini PL, Ferrari S, Alberghini M, Llombart-Bosch A, Piccolo E, Iacobelli S, Picci P, Scotlandi K (2010) Biological indicators of prognosis in Ewing’s sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). Int J Cancer 126(1):41–52PubMedCrossRefGoogle Scholar
  189. Zhan F, Tian E, Bumm K, Smith R, Barlogie B, Shaughnessy J Jr (2003) Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 101(3):1128–1140CrossRefGoogle Scholar
  190. Zhang X, Li L, Wei D, Yap Y, Chen F (2007) Moving cancer diagnostics from bench to bedside. Trends Biotechnol 25(4):166–173PubMedCrossRefGoogle Scholar
  191. Zoubek A, Dockhorn-Dworniczak B, Delattre O, Christiansen H, Niggli F, Gatterer-Menz I, Smith TL, Jurgens H, Gadner H, Kovar H (1996) Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 14(4):1245–1251Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Antonio Llombart-Bosch
    • 1
  • Ulrik Ringborg
    • 2
  • Sergio Rutella
    • 3
  • Julio E. Celis
    • 4
  1. 1.Department of PathologySchool of Medicine, University of ValenciaValenciaSpain
  2. 2.Cancer Center KarolinskaStockholmSweden
  3. 3.Department of HaematologyCatholic University and Immuno-Oncology Lab, IRCCS San RaffaeleRomeItaly
  4. 4.Institute of Cancer BiologyDanish Cancer SocietyCopenhagenDenmark

Personalised recommendations